Indeed, targeted therapies capable of binding HER2 and blocking the downstream signalling, such as trastuzumab, pertuzumab, lapatinib and trastuzumab emtansine (T-DM1), have significantly changed the prognosis of HER2-positive BC [3,6,8,9,10,11]. This evidence concerns the gene ERBB2 and breast cancer.